Eli Lilly Bets Big on Pennsylvania Plant, Fueling Weight-Loss Drug Ambitions and Valuation Debate
Eli Lilly's $3.5 billion investment in a new Pennsylvania facility for injectable weight-loss drugs, including retatrutide, spotlights its aggressive expansion in the obesity market. This strategic move, coupled with strong analyst sentiment and upcoming earnings, intensifies focus on the company's growth trajectory and premium valuation.